Wassil Jim 4

What Happened

• Wassil Jim, Chief Operating Officer of Vaxcyte (PCVX), received multiple equity awards and had shares withheld to cover tax obligations. The filing shows three grants: 32,045 RSUs (time‑based, $0 per share), 5,102 RSUs issued in lieu of a cash bonus (acquired at $61.74, total value $314,997), and a 53,566‑share derivative award (option/other, $0 stated).
• To satisfy tax withholding on vested RSUs, Jim surrendered 3,807 shares across three dates (1,900 @ $61.74 = $117,306; 898 @ $61.98 = $55,658; 1,009 @ $61.98 = $62,538), totaling $235,502 in withheld value. Net from the cash‑in‑lieu award: 5,102 granted → 3,807 withheld → about 1,295 shares remaining (≈$80k at ~ $61.7/share).
• Overall headline: ~90,713 shares were reported in awards/derivatives (32,045 + 5,102 + 53,566), but the majority (32,045 RSUs and 53,566 derivative shares) appear unvested per the filing.

Key Details

• Transaction dates and prices: 2/26/2026 (32,045 RSUs @ $0.00; 53,566 derivative @ $0.00), 2/27/2026 (5,102 RSUs @ $61.74, value $314,997; 1,900 shares surrendered @ $61.74), 2/28/2026 (898 shares surrendered @ $61.98), 3/02/2026 (1,009 shares surrendered @ $61.98).
• Total value reported for vested award: $314,997; total value surrendered for taxes: $235,502.
• Footnotes: F1 = standard time‑based RSU vesting schedule (1/4 on 9/7/2026 then 1/8 every six months); F2 = RSUs issued in lieu of a cash bonus and fully vested at grant; F3 = shares surrendered to cover tax withholding; F4 = derivative (option) vests 1/48 on 3/26/2026 then monthly thereafter.
• Shares owned after the transactions are not specified in the filing.
• Filing date: Form 4 filed 2026‑03‑02 for report period beginning 2026‑02‑26 — filing appears timely under the 2 business‑day rule.

Context

• The 5,102 RSUs were issued in lieu of a cash bonus and were fully vested at grant; the surrendered shares represent tax withholding (routine, not an open‑market sale).
• The larger 32,045 RSU award and the 53,566‑share derivative (option) award are subject to future vesting schedules and do not reflect immediate sell/buy market activity.
• These transactions are largely compensation and tax withholding events — common for executives — rather than open‑market purchases or discretionary sales.